Pfizer wins fast-track status for breast cancer drug palbociclib

04/12/2013 | PharmaTimes (U.K.)

The FDA granted breakthrough therapy designation to Pfizer's palbociclib as possible treatment for breast cancer patients. The decision was based on preliminary midstage trial results showing palbociclib's efficacy in improving median progression free survival in patients, in combination with letrozole.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ